X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
ELDER PHARMACEUTICALS LIMITED Fact Sheet - Equitymaster
Investing in India? Get Equitymaster Research  

ELDER PHARMACEUTICALS LIMITED  (ELDER)


Here is the latest financial fact sheet of Elder Pharma. For more details, see the Elder Pharma quarterly results and Elder Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
 
elder pharma - 1 Year Stock Price Chart
Loading...

 Price History
    Price Rs 38.0       No. of shares m 20.54
    Mkt Cap Rs m 781       % ch % 5.0
    Vol '000 20.5       % ch week % 5.0
    P/E X -0.2       % ch 1-mth % 27.1
    P/CF X 2.6       % ch 12-mth % -64.5
    EPS (TTM) Rs -220.6       52 week H/L Rs 118.8/20.4
(As on Sep 12, 2016 (Close)) »  Best Performing pharmaceuticals Stocks

Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!
 Financials

* Results Consolidated
No. of Months
Year Ending
12
Mar-11
*
12
Mar-12
*
12
Mar-13
*
15
Jun-13
*
12
Jun-14
*
5-Yr Chart
Click to enlarge
  EQUITY SHARE DATA
High Rs440435416416380 
Low Rs321298202202188 
Sales per share (Unadj.) Rs470.0649.8799.3799.3491.2 
Earnings per share (Unadj.) Rs31.335.240.140.1-3.2 
Diluted earnings per shareRs31.335.240.140.1-3.2 
Cash flow per share (Unadj.) Rs45.351.761.661.614.4 
Dividends per share (Unadj.) Rs3.003.00000 
Adj. dividends per shareRs3.003.000.000.000.00 
Dividend yield (eoy) %0.80.8000 
Book value per share (Unadj.) Rs307.0341.1374.5374.5376.5 
Adj. book value per shareRs307.0341.1374.5374.5376.5 
Shares outstanding (eoy) m20.5420.5420.5420.5420.54 
Bonus/Rights/Conversions  PP---- 
Price / Sales ratio x0.80.60.40.40.6 
Avg P/E ratio x12.210.47.77.7-89.3 
P/CF ratio (eoy) x8.47.15.05.019.7 
Price / Book Value ratio x1.21.10.80.80.8 
Dividend payout %9.68.5000 
Avg Mkt Cap Rs m7,8157,5286,3486,3485,833 
No. of employees `0003.63.5NANANA 
Total wages/salary Rs m1,2261,7992,3312,3312,179 
Avg. sales/employee Rs Th2,674.63,773.8NMNMNM 
Avg. wages/employee Rs Th339.7508.6NMNMNM 
Avg. net profit/employee Rs Th178.0204.3NMNMNM 
  INCOME DATA
Net Sales Rs m9,65313,34816,41716,41710,089 
Other income Rs m87265327327257 
Total revenues Rs m9,73913,61316,74416,74410,346 
Gross profit Rs m1,3311,9902,7342,734-792 
Depreciation Rs m287340441441361 
Interest Rs m2811,0161,5481,5482,756 
Profit before tax Rs m8499001,0711,071-3,653 
Minority Interest Rs m70000 
Prior Period Items Rs m80000 
Extraordinary Inc (Exp) Rs m-4515-28-283,713 
Tax Rs m177193219219125 
Profit after tax Rs m642723824824-65 
Gross profit margin %13.814.916.716.7-7.8 
Effective tax rate %20.821.420.520.5-3.4 
Net profit margin %6.75.45.05.0-0.6 
  BALANCE SHEET DATA
Current assets Rs m8,2788,7828,7918,7919,240 
Current liabilities Rs m5,8036,9579,9989,9989,998 
Net working cap to sales %25.613.7-7.4-7.4-7.5 
Current ratio x1.41.30.90.90.9 
Inventory Days Days9180545446 
Debtors Days Days10793898960 
Net fixed assets Rs m7,4258,9739,6319,63110,124 
Share capital Rs m206206206206206 
"Free" reserves Rs m5,4365,7906,1216,1215,582 
Net worth Rs m6,3077,0067,6937,6937,734 
Long term debt Rs m5,0955,8257,0397,0394,889 
Total assets Rs m17,41519,99824,92524,92522,882 
Interest coverage x4.01.91.71.7-0.3 
Debt to equity ratio x0.80.80.90.90.6 
Sales to assets ratio x0.60.70.70.70.4 
Return on assets %5.38.79.59.511.8 
Return on equity %10.210.310.710.7-0.8 
Return on capital %9.615.017.617.622.3 
Exports to sales %2.42.11.91.93.0 
Imports to sales %3.62.31.81.80.4 
Exports (fob) Rs m228280318318307 
Imports (cif) Rs m35130629129143 
Fx inflow Rs m228280318318307 
Fx outflow Rs m388334361361125 
Net fx Rs m-160-54-43-43181 
  CASH FLOW
From Operations Rs m 657 148 194 166 11,754 
From Investments Rs m -1,507 -1,711 -632 -632 -561 
From Financial Activity Rs m 2,734 433 -67 -39 -6,762 
Net Cashflow Rs m 1,885 -1,131 -506 -506 4,432 
* Results Consolidated Source: Company Annual Reports, Regulatory Filings, Equitymaster »  Historical quarterly results for elder pharmaceuticals limited

 Share Holding
Indian Promoters : 39.6%
Foreign collaborators : 0.0%
Indian inst/Mut Fund : 7.5%
FIIs : 16.8%
ADR/GDR : 0.0%
Free float : 36.1%
Shareholders : 16,479
Pledged promoter(s) holding : 77.6%
 Company Information
Top
    REGD OFF: Elder House, Plot No. C-9, Dalia Indl. Estate, Off Veera Desai Road, Mumbai-53
    E-MAIL: s.p.date@elderindia.com     WEB: www.elderindia.com
    TELEPHONE: (022) 2673 0058     FAX: (022) 2673 0051
    SECTOR: PHARMACEUTICALS     GROUP: MISCELLANEOUS
    TR AGENT: Intime Spectrum, C-13, Pannalal Silk Mills Compd., LBS Marg, Mumbai - 78
    AUDITOR: S. S. Khandelwal & Co.
CHM: J. Saxena COMP SEC: S. P. Date YEAR OF INC: 1900 BSE CODE: 532322 FV (Rs): 10 DIV YIELD (%): -

More pharmaceuticals Company Fact Sheets:   CIPLAAUROBINDO PHARMAVENUS REMEDIESFRESENIUS KABI ONCO.ASTRAZENECA PHARMA


Today's Market

French Presidential election and Oil Price Fall Impact Global Markets(RoundUp)

Investors were cautious ahead of the first round of the French Presidential elections ending next week. Fall in crude oil prices amidst oversupply concerns also adversely affected Global markets this week.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

Our Private Class with India's Value Investing Guru(The 5 Minute Wrapup)

Apr 19, 2017

Rohan and Kunal present you the discussions with professor Sanjay Bakshi in his virtual classroom.

Why Suddenly There is No Cash in ATMs(Vivek Kaul's Diary)

Apr 11, 2017

There have been a spate of media reports around ATMs not dispensing cash. What is really happening here?

HDFC Bank: The Solid Outperformer(Chart Of The Day)

Apr 22, 2017

Why HDFC Bank beat the Sensex by nearly 3 times.

The Real Reason Indiabulls Real Estate Jumped 42%(Daily Profit Hunter)

Apr 19, 2017

An elephant and six blind men will tell you more about the markets than any financial newspaper or channel.

Is PPF As An Investment Avenue Dead?(Outside View)

Apr 11, 2017

It's true, the interest on PPF has been lowered to 7.9%. PersonalFN evaluates if it's still a promising investment avenue.

More

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ELDER PHARMA

ELDER PHARMA - WOCKHARDT LTD. COMPARISON

Compare Company With Charts

COMPARE ELDER PHARMA WITH

MARKET STATS